Volv Global Poster: Early prediction of ARDS in community-acquired pneumonia patients using machine learning
Presenting new research on whether a machine learning model can flag which patients with CAP are most likely to progr...
Some of these diseases are rare. Others are common but easily missed, because their symptoms mirror something more familiar. Either way, patients often wait years for a diagnosis that names what is happening to them.
Volv Global works across a growing number of these conditions. Each disease page sets out the numbers behind it, the signs and symptoms most often missed, and how our work is helping close the gap to diagnosis and treatment.
A rare, inherited condition that often goes unrecognised for over a decade, as symptoms mimic more common diseases.
A hereditary condition strongly linked to COPD and liver disease, with most people who carry it never diagnosed.
A life-threatening lung condition that goes unrecognised in as many as 4 in 10 patients on the day it first appears.
A group of slow-growing but serious tumours whose vague, wide-ranging symptoms often delay diagnosis by years.
A rare muscle-wasting condition whose milder, later-onset form can take five to twelve years to diagnose.
Earlier triage of patients into a clinical trial before they are given traditional therapies.
Presenting new research on whether a machine learning model can flag which patients with CAP are most likely to progr...
Volv Global at ERS Congress 2026, presenting new research in collaboration with CSL Behring: Can We Catch ARDS Before...
Volv Global applied machine learning to 24M UK primary care records, surfacing ~1,200 undiagnosed GEP-NET patients, 5...
GEP-NETs are among the most diagnostically elusive tumours in oncology. This case study shows how machine learning ap...
Machine learning applied to 3,549 confirmed Pompe disease patients – the largest machine learning study of the diseas...
New research demonstrates that machine learning can map clinician-defined endpoints to real-world claims data in Pomp...
Explore Volv Global’s ISPOR 2026 research with Sanofi on Pompe disease, based on use of machine learning-driven endpo...
In Inflammatory Bowel Disease (IBD), steroids are considered a routine treatment, but repeated steroid exposure is a ...
AI-driven insights & RWD in Rare Disease: Accelerate AATD Diagnosis and identify undiagnosed AATD patients earlie...
Volv Global presented 2 posters at ATS 2025 showing work to assess how machine learning models can identify patients ...
A prediction model to identify symptomatic patients of different races and ethnicities with risk of Alpha-1 Antitryps...
Discover how Volv Global’s inTrigue AI helps identify rare disease patients earlier, improves diagnosis accuracy, and...